Protecting your kidneys during cisplatin or carboplatin chemotherapy
Official title: Effect of Sodium-Glucose Cotransporter 2 Inhibition on Urinary Biomarkers of Kidney Injury After Platinum-Based Chemotherapy
Run by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · NCT07018622 · Data updated 2026-11-12
This tests whether the diabetes medicine dapagliflozin can protect the kidneys of adults with solid tumors who are receiving cisplatin or carboplatin chemotherapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 46 (estimated) |
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Academic / other |
| Drugs / interventions | chemotherapy, methotrexate, cyclophosphamide |
| Locations | 1 site (México, Tlalpan) |
| Status | Recruiting |
| Started | May 7, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | October 30, 2026 |
| Registry record updated | March 11, 2026 |
| Trial ID | NCT07018622 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with solid tumors scheduled to receive cisplatin or carboplatin, with ECOG performance 0–2, expected survival >4 months, and eGFR ≥20 ml/min/1.73 m² who are not already on SGLT2 inhibitors and do not have uncontrolled diabetes or active urinary/kidney disorders.
✕Probably not a fit
Patients with severely reduced kidney function (eGFR <20 ml/min/1.73 m²), active glomerulopathy, unresolved obstructive uropathy, current use of other nephrotoxic drugs, prior nephrectomy or kidney transplant, or prior SGLT2 inhibitor exposure are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
DAPA-ARMOR is a phase 2, randomized, double-blind, placebo-controlled trial comparing dapagliflozin 10 mg daily to placebo in adults receiving platinum-based chemotherapy for solid tumors. Participants who meet eligibility receive study drug or placebo alongside their planned cisplatin or carboplatin regimens and undergo regular monitoring of kidney function, electrolytes, and biomarkers of proximal tubular injury. The trial measures rates of acute kidney injury, changes in eGFR and electrolyte disturbances, and chemotherapy interruptions or dose reductions related to nephrotoxicity. Key exclusions include very low baseline kidney function, prior SGLT2 inhibitor use, active urinary infection, kidney transplant, or recent nephrectomy.
Why it matters
Potential benefit: If successful, dapagliflozin could reduce platinum-induced kidney injury and help patients complete planned chemotherapy without dose reductions or delays.
How similar studies have gone: SGLT2 inhibitors have shown renal-protective effects in diabetic and non-diabetic chronic kidney disease, but their use specifically to prevent platinum-induced nephrotoxicity is largely novel with limited clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent form * Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin) * Expected survival \> 4 months * ECOG performance status 0-2 Exclusion Criteria: * History of nephrectomy * History of kidney transplant * Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate) * Type 1 diabetes mellitus * Poorly controlled type 2 diabetes (HbA1c \> 8% or fasting glucose \> 200 mg/dL in the past month) * Active glomerulopathy * Prior use of SGLT2 inhibitors or current indication for their use * eGFR \< 20 ml/min/1.73 m² * Active urinary tract infection * Unresolved obstructive uropathy * Participation in another clinical trial * History of recurrent genitourinary infections
Where it's running
-
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
México, Tlalpan, Mexico Recruiting
Study contacts
- Principal investigator: Juan M Mejía-Vilet, PhD — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Study coordinator: Erick Y Zuñiga, MD
- Email: erick.zunigag@incmnsz.mx
- Phone: + 52 55 5487 0900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.